Details
Stereochemistry | RACEMIC |
Molecular Formula | C21H27ClN2O2 |
Molecular Weight | 374.905 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc(cc1)C(c2ccc(cc2)Cl)N3CCN(CC3)CCOCCO
InChI
InChIKey=ZQDWXGKKHFNSQK-UHFFFAOYSA-N
InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2
DescriptionSources: http://www.drugbank.ca/drugs/DB00557Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011459s048,011795s025lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00557
Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011459s048,011795s025lbl.pdf
Hydroxyzine, a piperazine antihistamine structurally related to buclizine, cyclizine, and meclizine, is used to treat histamine-mediated pruritus or pruritus due to allergy, nausea and vomiting, and, in combination with an opiate agonist, anxiolytic pain. Hydroxyzine is also used as a perioperative sedative and anxiolytic and to manage acute alcohol withdrawal. Hydroxyzine competes with histamine for binding at H1-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The sedative properties of hydroxyzine occur at the subcortical level of the CNS. Secondary to its central anticholinergic actions, hydroxyzine may be effective as an antiemetic. It is used for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Leishmania (L.) infantum promastigotes viability Sources: https://www.ncbi.nlm.nih.gov/pubmed/24905294 |
59.57 µM [IC50] | ||
Target ID: CHEMBL231 Sources: http://www.drugbank.ca/drugs/DB00557 |
|||
Target ID: CHEMBL2993 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17447421 |
38.0 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | VISTARIL Approved UseFor symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.
Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. Launch Date7.8589441E11 |
|||
Palliative | VISTARIL Approved UseFor symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.
Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. Launch Date7.8589441E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
31.371 ng/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
72.5 ng/mL |
0.7 mg/kg bw single, oral dose: 0.7 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
72.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6141198/ |
0.7 mg/kg bw single, oral dose: 0.7 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
479.174 ng × h/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.4 h |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
20 h |
0.7 mg/kg bw single, oral dose: 0.7 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
20 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6141198/ |
0.7 mg/kg bw single, oral dose: 0.7 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYZINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg 3 times / day multiple, oral Highest studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, 19 - 34 yars n = 19 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 19 - 34 yars Sex: M+F Population Size: 19 Sources: |
Disc. AE: Drowsiness... Other AEs: Drowsiness, Dry mouth... AEs leading to discontinuation/dose reduction: Drowsiness (1 patient) Other AEs:Drowsiness (17 patients) Sources: Dry mouth (12 patients) Irritability (7 patients) Dizziness (3 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Drowsiness | 1 patient Disc. AE |
50 mg 3 times / day multiple, oral Highest studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, 19 - 34 yars n = 19 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 19 - 34 yars Sex: M+F Population Size: 19 Sources: |
Dry mouth | 12 patients | 50 mg 3 times / day multiple, oral Highest studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, 19 - 34 yars n = 19 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 19 - 34 yars Sex: M+F Population Size: 19 Sources: |
Drowsiness | 17 patients | 50 mg 3 times / day multiple, oral Highest studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, 19 - 34 yars n = 19 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 19 - 34 yars Sex: M+F Population Size: 19 Sources: |
Dizziness | 3 patients | 50 mg 3 times / day multiple, oral Highest studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, 19 - 34 yars n = 19 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 19 - 34 yars Sex: M+F Population Size: 19 Sources: |
Irritability | 7 patients | 50 mg 3 times / day multiple, oral Highest studied dose Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, 19 - 34 yars n = 19 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 19 - 34 yars Sex: M+F Population Size: 19 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/11290874/ Page: 5.0 |
likely | |||
yes [Ki 4 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12584158/ Page: 6.0 |
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Cardiovascular action of hydroxyzine (atarax). | 1956 Dec |
|
Circulatory and respiratory effects of hydroxyzine in volunteers and geriatric patients. | 1968 Jul-Aug |
|
Prolongation of simple and choice reaction times in a double-blind comparison of twice-daily hydroxyzine versus terfenadine. | 1989 Sep |
|
Prolonged penile erections induced by hydroxyzine: possible mechanism of action. | 1994 |
|
Hydroxyzine inhibits neurogenic bladder mast cell activation. | 1998 Oct |
|
[Pruritus without skin manifestation--what kind of state of the art nursing intervention?]. | 2003 Oct |
|
Hydroxyzine-induced supraventricular tachycardia in a nine-year-old child. | 2004 Feb |
|
[Preoperative psychopharmacological correction in women with focal breast diseases]. | 2005 May-Jun |
|
Neonatal seizures associated with maternal hydroxyzine hydrochloride in late pregnancy. | 2005 Nov-Dec |
|
[The use of atarax in the treatment of attention deficit syndrome with hyperactivity and anxiety]. | 2007 |
|
[Use of anxiolytic atarax as a substitutive drug for benzodiazepine tranquilizers]. | 2007 |
|
Pharmacologic attenuation of pelvic pain in a murine model of interstitial cystitis. | 2009 Nov 12 |
|
Characterization of anti-inflammatory properties and evidence for no sedation liability for the novel antihistamine SUN-1334H. | 2010 |
|
Chorea induced by antihistamine drugs. | 2010 Mar 15 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1. | 2013 Sep 5 |
|
Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. | 2014 Jun |
Patents
Sample Use Guides
For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: in adults, 50-100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50-100 mg daily in divided doses.
For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus: in adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50-100 mg daily in divided doses.
As a sedative when used as a premedication and following general anesthesia: 50-100 mg in adults, and 0.6 mg/kg in children.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9839659
Hydroxyzine reduced carbachol-induced serotonin release by 25% at 10(-6) M and 34% at 10(-5) M in rat bladder mast cells
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
492
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
||
|
NDF-RT |
N0000175750
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
||
|
NDF-RT |
N0000000207
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
||
|
WHO-VATC |
QN05BB01
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
||
|
WHO-ATC |
N05BB01
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
||
|
WHO-VATC |
QN05BB51
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
||
|
WHO-ATC |
N05BB51
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Hydroxyzine
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
3658
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
C29103
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
5553
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | RxNorm | ||
|
30S50YM8OG
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
3098
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
68-88-2
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
147152-21-4
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
SUPERSEDED | |||
|
M6159
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | Merck Index | ||
|
599
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
HYDROXYZINE
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
200-693-1
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
7199
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
D006919
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
1400
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
DB00557
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
CHEMBL896
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
SUB08088MIG
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY | |||
|
68-88-2
Created by
admin on Fri Jun 25 22:37:18 UTC 2021 , Edited by admin on Fri Jun 25 22:37:18 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE ACTIVE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)